COLLAGEN MEDICAL LLC
Belmont, MA · Medtech · Private
PET imaging probe (68Ga-CBP8) targeting type 1 collagen for non-invasive detection and quantification of radiation-induced lung injury
cmed.cc →- Grants
- $15M
- 23 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $2.5M
- 2 awards · Health and Human S
- #186 of 4531 in medtech
- Patents
- 9
- 1 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Health and Human Services · Igf::ot::igf Mr Contrast Agent To Quantify Myocardial Fibrosis - SBIR Topic 072 - Phase I | $915,741 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf SBIR Topic 85 To Support The Development Of Target Specific Molecular Imaging Agents In Combination With Existing Imaging Modalities To Detect High Risk Atherosclerotic Plaque. | $1,591,491 | |
| Federal grant | Department of Health and Human Services · Phase II · CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging | $427,371 | |
| Federal grant | Department of Health and Human Services · Phase II · CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging | $857,523 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Fibrin Targeted Cancer Therapy | $242,178 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Fibrin Targeted Cancer Therapy | $242,178 | |
| Federal grant | Department of Health and Human Services · Phase II · Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging | $430,152 | |
| Federal grant | Department of Health and Human Services · Phase II · Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer | $997,515 | |
| Federal grant | Department of Health and Human Services · Phase II · Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer | $1,002,483 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Imaging of Fibrosis in the Left Atrium | $295,301 | |
| Federal grant | Department of Health and Human Services · Phase II · Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer | $209,717 | |
| Federal grant | Department of Health and Human Services · Phase I · Magnetic Particle Detection Test for Vulnerable Carotid Plaque | $299,849 | |
| Federal grant | Department of Health and Human Services · Phase II · PET imaging of radiation induced lung injury | $399,990 | |
| Federal grant | Department of Health and Human Services · Phase II · Molecular Imaging Agent to Detect Thrombus | $496,849 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Imaging of Fibrosis in the Left Atrium | $766,000 | |
| Federal grant | Department of Health and Human Services · Phase I · New class of collagen-targeted contrast agents for Magnetic Resonance Imaging | $287,065 | |
| Federal grant | Department of Health and Human Services · Phase I · New class of collagen-targeted contrast agents for Magnetic Resonance Imaging | $287,065 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Imaging of Fibrosis in the Left Atrium | $725,517 | |
| Federal grant | Department of Health and Human Services · Phase II · PET imaging of radiation induced lung injury | $1,996,724 | |
| Federal grant | Department of Health and Human Services · Phase II · PET imaging of radiation induced lung injury | $1,191,390 | |
| Federal grant | Department of Health and Human Services · Phase II · PET imaging of radiation induced lung injury | $805,334 | |
| Federal grant | Department of Health and Human Services · Phase II · Theranostic for gastric cancer | $395,933 | |
| Federal grant | Department of Health and Human Services · Phase II · Theranostic for gastric cancer | $885,123 | |
| Federal grant | Department of Health and Human Services · Phase II · Theranostic for gastric cancer | $1,065,500 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 183 | LUMOSTECH, INC. | $2.7M | — |
| 184 | Sword Health | $2.6M | — |
| 185 | PACT & HEALTH LLC | $2.6M | — |
| 186 | COLLAGEN MEDICAL LLC | $2.5M | — |
| 187 | DILON TECHNOLOGIES INC | $2.5M | $22M |
| 188 | Wenzel Spine, Inc. | $2.5M | $4.9M |
| 189 | MICROMICS TECHNOLOGIES LLC | $2.5M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Collagen Imaging Compositionsgranted
- Collagen Imaging Compostionsapplication
- Collagen Imaging Compositionsapplication
- Collagen Imaging Compostionsapplication
- Collagen Imaging Compostionsapplication
- Contrast Agents For Collagen And Fibrin Imagingapplication
- Collagen Imaging Compositionsapplication
- Fibrin-binding Compounds For Imaging And Treatmentapplication
- Fibrin-binding Compounds For Imaging And Treatmentapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.